Lantheus (NASDAQ:LNTH) Stock Price Down 4.3% – Should You Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price dropped 4.3% during mid-day trading on Tuesday . The stock traded as low as $110.24 and last traded at $110.54. Approximately 296,201 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 953,683 shares. The stock had previously closed at $115.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on LNTH shares. B. Riley raised their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. JMP Securities reduced their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research report on Thursday, August 1st. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Leerink Partners raised their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a research note on Thursday, July 11th. Finally, Truist Financial decreased their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Lantheus Trading Down 20.7 %

The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The firm’s fifty day moving average is $108.04 and its two-hundred day moving average is $95.57. The firm has a market capitalization of $6.33 billion, a PE ratio of 14.95 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $378.73 million for the quarter, compared to the consensus estimate of $373.58 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. On average, equities analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current fiscal year.

Insider Activity

In related news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 2.10% of the company’s stock.

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Lantheus by 5.6% in the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after purchasing an additional 389,828 shares during the period. Farallon Capital Management LLC raised its holdings in Lantheus by 53.7% during the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after acquiring an additional 796,000 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after acquiring an additional 394,837 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Lantheus by 1.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after acquiring an additional 19,071 shares during the period. Finally, Swedbank AB boosted its holdings in shares of Lantheus by 21.1% in the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider’s stock worth $79,266,000 after acquiring an additional 125,843 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.